Cypress Asset Management Inc. TX decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,253 shares of the company’s stock after selling 3,935 shares during the period. Johnson & Johnson comprises 2.3% of Cypress Asset Management Inc. TX’s investment portfolio, making the stock its 6th biggest position. Cypress Asset Management Inc. TX’s holdings in Johnson & Johnson were worth $7,918,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. BlackRock Inc. lifted its stake in Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after acquiring an additional 7,853,141 shares in the last quarter. Boston Partners raised its position in Johnson & Johnson by 68.7% in the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after purchasing an additional 5,207,124 shares in the last quarter. Cornerstone Wealth Management LLC raised its position in Johnson & Johnson by 10,307.6% in the 2nd quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after purchasing an additional 2,473,105 shares in the last quarter. Bank of Montreal Can raised its position in Johnson & Johnson by 36.1% in the 2nd quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after purchasing an additional 1,833,622 shares in the last quarter. Finally, Summit Trail Advisors LLC raised its position in Johnson & Johnson by 11,692.6% in the 1st quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after purchasing an additional 1,752,841 shares in the last quarter. 66.70% of the stock is currently owned by hedge funds and other institutional investors.
In other news, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.
JNJ has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, October 14th. Jefferies Financial Group set a $145.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, July 15th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, Goldman Sachs Group raised Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $142.54.
JNJ opened at $140.68 on Friday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The stock has a market capitalization of $377.62 billion, a PE ratio of 19.27, a price-to-earnings-growth ratio of 2.20 and a beta of 0.70. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. The business had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. During the same quarter in the prior year, the business posted $1.90 EPS. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be issued a $0.90 dividend. The ex-dividend date is Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.56%. Johnson & Johnson’s payout ratio is currently 49.32%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Hedge Funds Explained
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.